Patch-Stage Mycosis Fungoides Versus Chronic Dermatitis
A 52-year-old man presents with a 3-year history of mildly pruritic erythematous patches on the buttocks, lower trunk, and thighs. He was treated for eczema with topical hydrocortisone and then triamcinolone 0.1% with partial improvement. A 4 mm punch biopsy shows a superficial perivascular lymphocytic infiltrate with mild epidermotropism and rare lymphocytes along the basal layer; there are no Pautrier microabscesses or significant atypia. Immunohistochemistry shows a CD4:CD8 ratio of 4:1 and partial loss of CD7. He has no lymphadenopathy, night sweats, or weight loss. His complete blood count and lactate dehydrogenase are normal. He asks whether this is eczema or lymphoma and whether he needs more tests.
1. Interpret the biopsy and immunohistochemistry. What is the differential diagnosis, and why can early mycosis fungoides be difficult to diagnose?
Read the worked answer
The biopsy shows a superficial lymphoid infiltrate with epidermotropism, a CD4-predominant T-cell population, and partial loss of CD7. These features raise concern for early patch-stage mycosis fungoides, but they are not diagnostic on their own.
Differential diagnosis: chronic spongiotic dermatitis, psoriasis, drug eruption, pityriasis lichenoides, and other benign inflammatory dermatoses. Early mycosis fungoides is notoriously difficult to diagnose because the infiltrate may be sparse and the epidermotropism subtle. Pautrier microabscesses are often absent in early disease, and significant cytologic atypia may not be seen. Benign dermatoses can also show CD4 predominance and some CD7 loss.
The key is clinicopathologic correlation: persistent, slightly scaly patches in a bathing-trunk distribution, poor response to conventional eczema therapy, and progressive lesions support mycosis fungoides. A single biopsy cannot always distinguish early disease from dermatitis. Repeat biopsy from a new or untreated lesion, and review by a dermatopathologist, are often necessary.
2. Which ancillary tests would you order, and how would you use the results in counseling the patient?
Read the worked answer
Ancillary tests:
- T-cell receptor gene rearrangement studies by PCR on the biopsy tissue. A clonal result supports mycosis fungoides but is not specific; clonal rearrangements can occur in benign dermatoses.
- Additional immunohistochemistry, including CD26 and CD7 loss on CD4+ cells, can increase diagnostic confidence.
- Repeat biopsy from an untreated or progressive lesion if the diagnosis remains uncertain.
- Blood flow cytometry for Sezary cells is not routine in early patch-stage disease but is reasonable if there is erythroderma, lymphadenopathy, or abnormal blood counts.
- Lymph node examination and imaging are not indicated without palpable nodes or systemic symptoms.
Counseling: Explain that mycosis fungoides is a cutaneous T-cell lymphoma but that early patch-stage disease usually has an indolent course and is treated with skin-directed therapy. A clonal TCR result alone does not prove cancer, and a negative result does not exclude it. Emphasize the need for regular follow-up and repeat biopsy if lesions change.
3. Outline initial management and follow-up for early-stage mycosis fungoides.
Read the worked answer
Initial management:
- Topical corticosteroids (for example, triamcinolone 0.1% or clobetasol 0.05% for thicker patches) to reduce inflammation and symptoms.
- Narrowband UVB three times weekly is first-line for widespread patch-stage disease. It is well tolerated and can induce remission. Protect unaffected skin and monitor cumulative dose.
- Emollients and treatment of secondary infection if present.
- Avoid systemic chemotherapy in early-stage disease; it does not improve survival and adds toxicity.
Follow-up:
- Review every 3–6 months, documenting body surface area, lesion thickness, and lymph node examination.
- Photograph representative areas to track progression.
- Repeat biopsy if a lesion becomes thicker, ulcerated, or resistant to therapy.
- If progression to plaque or tumor stage occurs, refer to a multidisciplinary cutaneous lymphoma team for consideration of photopheresis, radiation, or systemic therapy.
Counseling: Reassure that early-stage disease is often chronic and manageable, but long-term follow-up is essential because progression can occur years later.